847029-99-6

Basic information

• Product Name: 4-HYDROXY-PIPERIDINE-1,2-DICARBOXYLIC ACID 1-BENZYL ESTER 2-METHYL ESTER
• Synonyms: 4-HYDROXY-PIPERIDINE-1,2-DICARBOXYLIC ACID 1-BENZYL ESTER 2-METHYL ESTER
• CAS NO: 847029-99-6
• Molecular Formula: C₁₅H₁₉NO₅
• Molecular Weight: 293.32
• Mol File: 847029-99-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-HYDROXY-PIPERIDINE-1,2-DICARBOXYLIC ACID 1-BENZYL ESTER 2-METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-PIPERIDINE-1,2-DICARBOXYLIC ACID 1-BENZYL ESTER 2-METHYL ESTER(847029-99-6)
• EPA Substance Registry System: 4-HYDROXY-PIPERIDINE-1,2-DICARBOXYLIC ACID 1-BENZYL ESTER 2-METHYL ESTER(847029-99-6)

Safety Data

• Hazardous Substances Data: 847029-99-6(Hazardous Substances Data)

Upstream product

• 144913-66-6 4-hydroxy-2-piperidine carboxylic acid methyl ester 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 144913-66-6 4-hydroxy-2-piperidine carboxylic acid methyl ester 
• 845256-73-7 benzyl 4-[(tert-Butoxycarbonyl)(methyl)amino]-2-(hydroxymethyl)piperidine-1-carboxylate 
• 1259012-00-4 tert-butyl 2-((2-(5-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)methyl)-4,4-difluoropiperidine-1-carboxylate 
• 1259011-99-8 (±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate 
• 1255666-28-4 1-tert-butyl 2-methyl 4,4-difluoropiperidine-1,2-dicarboxylate 
• 1259011-96-5 (±)-methyl 1-benzyloxycarbonyl-4,4-difluoropiperidine-2-carboxylate 
• 125104-19-0 (±)-methyl 1-benzyloxycarbonyl-4-oxopiperidine-2-carboxylate 

Relevant articles and documents

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

PROBLEM TO BE SOLVED: To provide inhibitors of influenza virus replication. SOLUTION: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient comprise administering to the biological sample or patient an effective amount of a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A compound is represented by structural formula (IA) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. COPYRIGHT: (C)2015,JPO&INPIT

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.